Core Viewpoint - Rongchang Biopharma (688331.SH) experienced a significant decline in stock price, closing at 87.20 yuan with an 8.31% drop on October 23 [1] Financial Performance - Huatai Securities analysts maintained the forecast for Rongchang Biopharma's net profit attributable to shareholders for 2025-2027 at 3.46 million yuan, 0.03 million yuan, and 5.36 million yuan respectively [1] - The report retained a Weighted Average Cost of Capital (WACC) of 6.5% and a perpetual growth rate of 2.5% [1] Valuation and Ratings - The target price for A-shares based on Discounted Cash Flow (DCF) is set at 138.89 yuan, with an adjustment of the A/H premium to 8.67%, consistent with the past three months [1] - The target price for H-shares is adjusted to 139.96 HKD from a previous 137.10 HKD, with both A and H shares maintaining a "Buy" rating [1]